Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions.
暂无分享,去创建一个
T Suzuki | A. Sugawara | H. Sasano | N. Ohuchi | Y. Miki | T. Ishida | S. Hayashi | N Ohuchi | T. Moriya | T. Suzuki | Y Nakamura | T Moriya | H Sasano | S Hayashi | Y Miki | A Sugawara | T Ishida | Y. Nakamura
[1] M. Kilgore,et al. The Increased Expression of Peroxisome Proliferator-Activated Receptor-γ1 in Human Breast Cancer Is Mediated by Selective Promoter Usage , 2004, Cancer Research.
[2] Martin C Frith,et al. Genomic targets of nuclear estrogen receptors. , 2004, Molecular endocrinology.
[3] G. Watkins,et al. The localisation and reduction of nuclear staining of PPARgamma and PGC-1 in human breast cancer. , 2004, Oncology reports.
[4] D. Crowe,et al. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands , 2004, Breast Cancer Research.
[5] John H. White,et al. Genome-wide identification of high-affinity estrogen response elements in human and mouse. , 2004, Molecular endocrinology.
[6] M. Kurosumi,et al. Prediction of prognosis of estrogen receptor‐positive breast cancer with combination of selected estrogen‐regulated genes , 2004, Cancer science.
[7] A. Sugawara,et al. Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.
[8] P. Fisher,et al. Up-regulation of p21 Gene Expression by Peroxisome Proliferator-Activated Receptor γ in Human Lung Carcinoma Cells , 2004, Clinical Cancer Research.
[9] G. Firestone,et al. Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest , 2004, Cancer Research.
[10] R. Mansel,et al. Expression of peroxisome‐proliferator activated receptor‐gamma (PPARγ) and the PPARγ co‐activator, PGC‐1, in human breast cancer correlates with clinical outcomes , 2003 .
[11] D. Gold,et al. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. , 2003, Cancer research.
[12] J. Shih,et al. Tumor-associated antigen L6 and the invasion of human lung cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] B. Spiegelman,et al. Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study , 2003, Breast Cancer Research and Treatment.
[14] K. Tanimoto,et al. The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. , 2003, Endocrine-related cancer.
[15] N. Pavlidis,et al. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. , 2003, Breast.
[16] V. Kosma,et al. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis , 2003, Journal of clinical pathology.
[17] M. Marino,et al. Synergism between Genomic and Non Genomic Estrogen Action Mechanisms , 2003, IUBMB life.
[18] S. Safe,et al. Peroxisome Proliferator-activated Receptor γ Agonists Induce Proteasome-dependent Degradation of Cyclin D1 and Estrogen Receptor α in MCF-7 Breast Cancer Cells , 2003 .
[19] Y. Yano,et al. Peroxisome Proliferator‐activated Receptor Gamma Activation Induces Cell Cycle Arrest via the p53‐independent Pathway in Human Anaplastic Thyroid Cancer Cells , 2002, Japanese journal of cancer research : Gann.
[20] T. Yamori,et al. Development of cDNA microarray for expression profiling of estrogen-responsive genes. , 2002, Journal of molecular endocrinology.
[21] Y. Omoto,et al. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells , 2002, Molecular and Cellular Endocrinology.
[22] F. Speleman,et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.
[23] T. Willson,et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. , 2002, Biochemistry.
[24] A. Shuldiner,et al. The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity , 2002, Current diabetes reports.
[25] K. Walsh,et al. Decorin-mediated Signal Transduction in Endothelial Cells , 2001, The Journal of Biological Chemistry.
[26] S. Nakashima,et al. MDM2 Enhances the Function of Estrogen Receptor α in Human Breast Cancer Cells , 2001 .
[27] H. Nischalke,et al. Semi-quantification of human C-C chemokine mRNAs with reverse transcription/real-time PCR using multi-specific standards. , 2000, Journal of immunological methods.
[28] H. Peterse,et al. p27kip1 expression in breast carcinomas: An immunohistochemical study on 512 patients with long‐term follow‐up , 2000 .
[29] V. Seewaldt,et al. Peroxisome proliferator-activated receptor gamma activation in human breast cancer. , 1999, International journal of oncology.
[30] K. Chien,et al. PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .
[31] R. Bouvier,et al. Differential RNA expression of the pS2 gene in the human benign and malignant prostatic tissue. , 1999, Prostate cancer and prostatic diseases.
[32] T. Zacharewski,et al. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers , 1999, Breast Cancer Research and Treatment.
[33] S. Safe,et al. Transcriptional Activation of Insulin-Like Growth Factor-Binding Protein-4 by 17β-Estradiol in MCF-7 Cells: Role of Estrogen Receptor-Sp1 Complexes. , 1999, Endocrinology.
[34] M. Michikawa,et al. Enhancement of MTT, a tetrazolium salt, exocytosis by amyloid β-protein and chloroquine in cultured rat astrocytes , 1999, Neuroscience Letters.
[35] H. Sprecher,et al. Estrogen-induced Production of a Peroxisome Proliferator-activated Receptor (PPAR) Ligand in a PPARγ-expressing Tissue* , 1998, The Journal of Biological Chemistry.
[36] P. Kolattukudy,et al. Peroxisome proliferator‐activated receptor γ1 (PPAR‐γ1) as a major PPAR in a tissue in which estrogen induces peroxisome proliferation , 1998 .
[37] H P Koeffler,et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[38] B. Spiegelman,et al. Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.
[39] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[40] M. Fan,et al. Lymph node micrometastases from breast carcinoma , 1997, Cancer.
[41] S. Safe,et al. Identification of a functional imperfect estrogen-responsive element in the 5'-promoter region of the human cathepsin D gene. , 1997, Biochemistry.
[42] A. Marchetti,et al. Cyclin‐d1‐gene amplification and expression in breast carcinoma: Relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21waf1 immunohistochemical expression , 1997, International journal of cancer.
[43] J Auwerx,et al. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.
[44] R. Evans,et al. The RXR heterodimers and orphan receptors , 1995, Cell.
[45] J. Lehmann,et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.
[46] W. Wahli,et al. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. , 1995, Molecular endocrinology.
[47] A. Sugawara,et al. Isoform-specific retinoid-X receptor (RXR) antibodies detect differential expression of RXR proteins in the pituitary gland. , 1995, Endocrinology.
[48] K. Korach. Insights from the study of animals lacking functional estrogen receptor. , 1994, Science.
[49] B. Spiegelman,et al. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.
[50] S. Ben‐Sasson,et al. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.
[51] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[52] P. Chambon,et al. Functional domains of the human estrogen receptor , 1987, Cell.
[53] W. McGuire,et al. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. , 1978, The Journal of biological chemistry.
[54] M. Zanetti,et al. Estrogen-directed synthesis of specific prostaglandins in uterus. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[55] G. Firestone,et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. , 2004, Cancer research.
[56] T. Okumura,et al. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells , 2004, International journal of cancer.
[57] A. Sugawara,et al. Retinoid Receptors in Human Breast Carcinoma: Possible Modulators of in Situ Estrogen Metabolism , 2004, Breast Cancer Research and Treatment.
[58] H. Koeffler. Peroxisome proliferator-activated receptor gamma and cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[59] R. Mansel,et al. Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. , 2003, International journal of cancer.
[60] A. Badawi,et al. Expression of cyclooxygenase‐2 and peroxisome proliferator‐activated receptor‐γ and levels of prostaglandin E2 and 15‐deoxy‐Δ12,14‐prostaglandin J2 in human breast cancer and metastasis , 2003 .
[61] H. Koeffler. Peroxisome proliferator-activated receptor γ and cancers , 2003 .
[62] S. Safe,et al. Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. , 2003, Cancer research.
[63] D. Gold,et al. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. , 2003, Cancer research.
[64] S. Saji,et al. MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. , 2001, Biochemical and biophysical research communications.
[65] H. Peterse,et al. p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. , 2000, International journal of cancer.
[66] R. Evans,et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. , 1999, Molecular cell.
[67] S. Kitano,et al. G-Protein g 7 Is Down-Regulated in Cancers and Associated with P 27 -induced Growth Arrest , 1999 .
[68] S. Safe,et al. Transcriptional activation of insulin-like growth factor-binding protein-4 by 17beta-estradiol in MCF-7 cells: role of estrogen receptor-Sp1 complexes. , 1999, Endocrinology.
[69] P. Kolattukudy,et al. Peroxisome proliferator-activated receptor gamma1 (PPAR-gamma1) as a major PPAR in a tissue in which estrogen induces peroxisome proliferation. , 1998, FEBS letters.
[70] W. Wahli,et al. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.
[71] B. O’Malley,et al. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.
[72] M. Rio,et al. Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells. , 1988, Cancer treatment and research.